<DOC>
	<DOCNO>NCT01317199</DOCNO>
	<brief_summary>This research do test investigational product call Muscadine Plus treatment men receive initial therapy ( surgery radiation , cryotherapy brachytherapy ) prostate cancer experience rise prostate-specific antigen ( PSA ) level .</brief_summary>
	<brief_title>Effects Two Doses MPX Capsules Rising Prostate-specific Antigen Levels Men Following Initial Therapy Prostate Cancer</brief_title>
	<detailed_description>In phase I investigators evaluate safety product check blood level active component . In phase II investigator evaluate effect MPX PSA double time</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma prostate . Undergone definitive treatment ( surgery , surgery radiation therapy , cryotherapy , radiation therapy brachytherapy ) primary prostate tumor . Rising PSA minimum 3 time point ( include screen psa ) within 12 month prior study initiation . &gt; 18 year age . Life expectancy great 6 month . ECOG performance status 0 , 1 2 . Testosterone level â‰¥1.5 ng/mL screen . Adequate kidney , liver bone marrow function Agrees abstain commercially available MP product participate study . Subject 's use dietary/herbal supplement ( e.g . saw palmetto , selenium , etc ) stable least 2 month prior screen subject agrees stop change dose ( ) participate study . Signed write informed consent document agree comply requirement study . Known radiographic evidence metastatic disease , except presence positive lymph node surgical pathology . Pelvic/intraperitoneal lymph node le 2.0 cm maybe consider nonspecific patient would eligible Receipt therapy modulate testosterone level ( e.g. , androgen ablative/antiandrogen therapy , 5 alpha reductase inhibitor ) minimum 6 month prior study Prior concomitant treatment experimental drug , high dose steroid , cancer treatment within 4 week prior first dose study product Consumption Muscadine Plus past 2 month Known allergy muscadine grape ellagic acid Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Negative PSA double time ( 1 time point may exclude per 3e inclusion criterion )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Rising psa</keyword>
</DOC>